CNCR 15.10 Loncar Cancer Immunotherapy ETF
| Range: | 9.22-17.96 | Vol Avg: | 3869 | Last Div: | 0 | Changes: | 0.15 |
| Beta: | 0.91 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Financial Services | IPO: | Wed Oct 14 2015 | Empoloyees: | |||
| CUSIP: | 26922A826 | CIK: | 0001540305 | ISIN: | US26922A8264 | Country: | US |
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Stock Details
Positive 0.39
4 Solid ETFs Under $20 for Your Portfolio
Low-priced ETFs could be attractive for investors as these enable them to buy more shares ...
zacks.com·Thu Oct 10 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow